StockData
enGene Therapeutics Inc. logo

enGene Therapeutics Inc. (ENGN) stock

ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 8, 2026Score 3/30
$1.72−0.17 (-8.99%)

Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%

enGene Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

enGene Therapeutics's pe ratio was 0.2× on Nov 30, 2023.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Nov 30, 20230.2×–

More enGene Therapeutics figures

See a number that looks wrong?